Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
Sponsor: Ribocure Pharmaceuticals AB
Phase: 2
Disease: Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism, Cancer-associated venous thromboembolism
EU trial number: 2026-525479-15-00
Population: Adults in two venous thromboembolism (VTE)-risk cohorts: participants with prior symptomatic proximal deep vein thrombosis and/or pulmonary embolism who completed 3–12 months of anticoagulation and are at clinical equipoise regarding extended therapy, and ambulatory patients with active solid tumors or lymphoma initiating at least 3 months of systemic cytotoxic chemotherapy with a Khorana score of at least 2. Participants must not have high bleeding risk or a clear indication for ongoing anticoagulation.
Register Investigator Interest
Interested in offering this trial to suitable patients?